非索罗定对链脲佐菌素诱导的糖尿病大鼠勃起功能障碍的有益作用
研究纳入16只成年雄性Sprague-Dawley大鼠,平均分为对照组和糖尿病组,糖尿病经单次静脉注射链脲佐菌素(25-35 mg/kg)诱导。结果显示,海绵体内注射非索罗定(1 µM)可恢复糖尿病大鼠在5.0和7.5 V刺激水平下的勃起反应,并使基础海绵体内压从5.4 ± 0.9 mm Hg显著升高至33.9 ± 7.9 mm Hg(P <.001)。作者结论认为非索罗定改善勃起功能及海绵体条带舒张,机制可能为阻断L型钙通道,不依赖一氧化氮-环磷酸鸟苷通路,但需进一步研究。
要点
- 非索罗定(1 µM)海绵体内注射可恢复糖尿病大鼠5.0和7.5 V水平勃起反应,2.5 V未恢复。
- 糖尿病大鼠基础海绵体内压由5.4 ± 0.9 mm Hg升至33.9 ± 7.9 mm Hg(P <.001)。
- 硝苯地平抑制非索罗定最大舒张58%,提示L型钙通道参与,不依赖NO-cGMP通路。
核心结论
- 非索罗定改善勃起功能及离体大鼠海绵体条带舒张,机制可能为阻断L型钙通道且不依赖一氧化氮-环磷酸鸟苷通路。
- 作者认为需进一步研究以充分阐明非索罗定对膀胱过度活动相关糖尿病勃起功能障碍的恢复作用。
研究设计与样本
- 动物实验:16只成年雄性Sprague-Dawley大鼠,平均分为对照组和糖尿病组。
- 糖尿病经单次静脉注射链脲佐菌素(25-35 mg/kg)诱导。
- 在体勃起反应通过刺激海绵体神经评估,并在海绵体内注射非索罗定(1 µM)后重复测量。
- 离体海绵体条带舒张反应在非索罗定(10 µM)存在或不存在时观察,并以多种抑制剂孵育检验舒张机制。
主要发现
- 糖尿病大鼠海绵体内注射非索罗定后,5.0和7.5 V水平在体勃起反应恢复,2.5 V未恢复。
- 糖尿病大鼠基础海绵体内压为5.4 ± 0.9 mm Hg,注射非索罗定后升至33.9 ± 7.9 mm Hg(P <.001)。
- 浴槽研究中非索罗定引起海绵体浓度依赖性舒张,该舒张在糖尿病大鼠中减弱。
- 硝苯地平(L型Ca2+通道阻滞剂)抑制非索罗定诱导的最大舒张58%。
- 非选择性K+通道阻滞剂四乙铵和格列本脲孵育未改变非索罗定的舒张反应。
关键数值与推荐
- 糖尿病诱导:链脲佐菌素单次静脉注射25-35 mg/kg。
- 在体勃起评估刺激电压:2.5、5.0、7.5 V。
- 海绵体内注射非索罗定浓度:1 µM;浴槽孵育浓度:10 µM。
- 基础海绵体内压:糖尿病大鼠5.4 ± 0.9 mm Hg,注射非索罗定后33.9 ± 7.9 mm Hg(P <.001)。
- 硝苯地平抑制非索罗定最大舒张58%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者结论指出需进一步研究以充分阐明非索罗定对膀胱过度活动相关糖尿病勃起功能障碍的恢复作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the possible role of fesoterodine (a competitive muscarinic receptor antagonist) on erectile dysfunction in streptozotocin-induced diabetic rats. MATERIALS AND METHODS: A total of 16 adult male Sprague-Dawley rats were equally divided into control and diabetic groups. Diabetes was induced by a single intravenous injection of streptozotocin (25-35 mg/kg). In vivo erectile responses were evaluated by the stimulation of cavernosal nerves, and measurements were repeated after the intracavernosal injection of fesoterodine (1 µM) in rats. The relaxation responses to fesoterodine were examined via incubation with various inhibitors. The relaxant responses of corpus cavernosum (CC) strips were observed in the presence or the absence of fesoterodine (10 µM). RESULTS: Intracavernous administration of fesoterodine restored in vivo erectile response at 5.0- and 7.5-V levels, except for 2.5 V in diabetic rats. Basal intracavernosal pressure (5.4 ± 0.9 mm Hg) in diabetic rats was markedly increased after injection of fesoterodine (33.9 ± 7.9 mm Hg, P <.001). In bath studies, fesoterodine resulted in a relaxation of CC in a concentration-dependent manner, which was reduced in diabetic rats. Nifedipine (l-type Ca2+ channel blocker) inhibited maximum fesoterodine-induced relaxation by 58%. The nonselective K+ channel blocker tetraethylammonium and glibenclamide incubation did not change the relaxant response to fesoterodine. The relaxant responses to acetylcholine (10 µM), electrical field stimulation (10 Hz), and sodium nitroprusside (0.01 µM) in diabetic rats were increased after incubation with fesoterodine (10 µM). CONCLUSION: Fesoterodine improved erectile function and relaxation of isolated strips of rat CC. The underlying mechanism of fesoterodine is likely due to the blocking of l-type calcium channels independent of the nitric oxide-cyclic guanosine monophosphate pathway. Further investigations are warranted to fully elucidate the restorative effects of fesoterodine on overactive bladder-induced diabetic erectile dysfunction.
引用
- Yilmaz-Oral D, Bayatli N, Gur S, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats. Urology. 2017. PMID: 28579067. doi:10.1016/j.urology.2017.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。